|Mr. Andrew Obenshain||Pres, CEO & Director||842.85k||N/A||1975|
|Mr. Jason F. Cole Esq.||Treasurer, Principal Accounting Officer & Financial Officer and Chief Strategy & Financial Officer||838.97k||N/A||1973|
|Mr. Thomas J. Klima||Chief Commercial Officer||509.7k||N/A||1972|
|Mr. Kasra Kasraian||Sr. VP of Technical Devel. & Operations||N/A||N/A||N/A|
|Ms. Jessica Whitten||VP, Global Controller & Chief Accounting Officer||N/A||N/A||1977|
|Ms. Helen C. Fu||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||N/A|
|Ms. Elizabeth Pingpank||Director of Corp. Communications||N/A||N/A||N/A|
|Sarah Alspach||Chief Communications Officer||N/A||N/A||N/A|
|Ms. Meredith Willoughby||VP of People & Culture||N/A||N/A||N/A|
|Dr. Liviu Niculescu M.D., Ph.D.||Sr. VP of Global Medical Affairs||N/A||N/A||N/A|
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc.’s ISS governance QualityScore as of 1 July 2022 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 5; Compensation: 7.